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Tissue &hernia leads to adenosine triphosphate (ATP) breakdown 
with elevation of body fluid ATP metabolites. Thii study tests the 
hypothesis that there is a direct relationship between periods of hypo- 
tension and body fluid uric acid and oxypurine levels in 19 prospective- 
ly studied patients. Significant elevations in urine oxypurine/creatinine 
clearance were found during periods of hypotension as compared with 
nonhypotensive periods (p <O.OS). During severe episodes of hypo- 
tension, the serum urate level was significantly elevated as well (p 
<0.05). The increase in these body fluid products of ATP degradation 
may reflect cellular ischemia during hypotensive periods. There was a 
weak correlation (r = -0.31, p <O.OOl) between the systolic blood 
pressure and urine oxypurine/creatinine clearance. However, variabil- 
ity in the appearance of body fluid ATP breakdown products during 
episodes of hypotension suggests the interplay of multiple factors in the 
degradation of ATP. The use of ATP degradation products to quantitate 
the physiologic significance of clinical events remains tantalizing but 
not proved. 
Hypoxia at the cellular level results in profound metabolic changes. The 
equilibrium between consumption and production of adenosine triphos- 
phate (ATP), the basic energy source for cellular metabolism, is disrupt- 
ed. ATP is converted to adenosine diphosphate (ADP) and adenosine 
monophosphate (AMP). Further metabolism to purine degradation prod- 
ucts including adenosine, inosine, hypoxanthine, xanthine, and uric acid 
may occur [l] (see Figure 1). Decreased tissue ATP levels and the 
appearance of elevated ATP degradation products, evidence of cellular 
hypoxia, have been observed in models of shock [2-91, and in patients 
with severe cardiac failure [ 10,i I], cardiogenic shock [lo], reversible 
cardiac arrest [ 121, and perinatal distress [ 13-2 11. 
The extent of tissue ATP loss was directly related to the severity and 
duration of shock in animal models [2-61. In human studies, there are 
modest correlations between elevated body fluid purine degradation 
products and clinical measures of antecedent hypoxia [ 15 17, 191, and 
neurologic damage at birth [20]. However, the duration and extent of the 
tissue hypoxia could only be inferred, making interpretation of changes in 
body fluid ATP breakdown products difficult. 
This study was designed to prospectively test the hypothesis that there 
is a direct relationship between tissue hypoxia and an increase in body 
fluid purine levels resulting from ATP degradation. Hypotension was 
chosen as an indicator for tissue ischemia because it could be easily and 
repetitively measured clinically. The following questions were addressed: 
(1) Does hypotension result in elevation of levels of body fluid uric acid 
472 September 1988 The American Journal of Medicine Volume 81 
and oxypurines (hypoxanthine and xanthine)? (2) Is there 
consistent elevation of body fluid purine levels during 
hypotensive episodes? (3) Does the magnitude of 
changes in body fluid purine levels correlate with the 
extent of antecedent hypotension? 
PATIENTS AND METHODS 
Patients. Nineteen patients admitted to the University of 
Michigan medical intensive care unit during a three-month 
period were selected for study (Table I). Patients were 
included only if they were observed for at least 32 hours in 
the intensive care unit, were not in the postsurgical period, 
initially had adequate urine output, and most importantly, 
were clinically judged by one of us (J.O.W.) as being criti- 
cally ill with a high potential for severe medical complica- 
tions. All patients were followed prospectively until trans- 
ferred from the medical intensive care unit or until death. 
Clinical Measurements. In addition to the standard physi- 
ologic and laboratory monitoring, patients in the study had 
continuous urine collections divided into three eight-hour 
observation periods daily. Serum urate levels and urinary 
uric acid and oxypurine (hypoxanthine and xanthine) excre- 
tion were measured by enzymatic spectrophotometric 
methods [22,23]. Urine creatinine was measured by an 
automated Jaffe reaction [24]. Serum creatinine values 
were measured in the Clinical Chemistry Laboratory of the 
University of Michigan Medical Center. 
Urinary excretion of purine compounds is dependent 
upon renal function. To correct for variation in renal func- 
tion, the ratio of urine uric acid and oxypurine excretion to 
creatinine clearance was calculated for each observation 
period. Although the patients were not in a steady state, the 
creatinine clearance was determined as the best approxi- 
mation of renal function. 
Definitions of Hypotension. For initial analysis, a hype 
tensive observation period was defined as an observation 
period with a low recorded systolic blood pressure of 90 
mm Hg or less. All observation periods with a low recorded 
systolic blood pressure of more than 90 mm Hg were 
defined as nonhypotensive periods for this analysis. In each 
patient with at least one hypotensive period, the means of 
the serum urate, urine uric acidicreatinine clearance, and 
urine oxypurine/creatinine clearance from all such periods 
were compared with the means from all nonhypotensive 
periods in the same patient. The change in body fluid purine 
levels during hypotensive periods was calculated as a per- 
cent of control by dividing the means from the hypotensive 
periods by the means from the nonhypotensive periods. 
The second analysis focused on discrete episodes of 
hypotension in individual patients. A hypotensive episode 
was defined as including all contiguous observation periods 
with a recorded low systolic blood pressure of 90 mm Hg or 
less. Each such hypotensive episode was compared with all 
contiguous nonhypotensive observation periods (low sys- 
tolic blood pressure of more than 90 mm Hg) immediately 
preceding or following the hypotensive episode. This com- 
parison nonhypotensive group was bounded by the hypo- 
tensive episode under consideration and another hypoten- 
sive episode or the cessation or beginning of intensive care 
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Figure 1. Purine degrada t/on path way. 
unit monitoring. The change in serum urate, urine uric 
acidlcreatinine clearance, and urine oxypurinelcreatinine 
clearance was again calculated as a percent of control by 
dividing the means from the hypotensive episode by the 
means from the adjacent nonhypotensive periods. 
To further restrict the analysis to the severe hypotensive 
episodes, observation periods with a low recorded systolic 
blood pressure of 90 mm Hg or less and a mean systolic 
blood pressure of 105 mm Hg or less were identified. The 
means from all such contiguous observation periods were 
compared with the means of the body fluid purine levels 
from all normal periods (low systolic blood pressure more 
than 100 mm Hg and mean blood pressure more than 105 
mm Hg) that were Immediately adjacent-either prior to or 
after-the severe hypotensive episode in that person. The 
change in body fluid purine levels during the severe hypo- 
tensive episode was calculated as a percent of the control 
normal periods. The mean systolic blood pressure was 
determined by taking the mean of all systolic blood pres- 
sures recorded during each eight-hour observation period. 
The frequency of blood pressure measurement was vari- 
able depending upon the status of the patient. When pa- 
tients’ conditions were unstable, more frequent vital signs 
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TABLE I Characteristics of Study Patients 
Patient Age and Sex 
Total Number of 
Observation Periods 
Number of Observation 
Periods with 
Systolic Blood Pressure 
Measurements 190 mm Hg Disease 
1 69F 23 2 
2 82M 16 0 
3 65F 47 5 
4 16F 4 3 
5 24F 8 0 
6 54F 6 0 
7 47F 16 0 
8 51M 42 2 
9 64F 5 0 
10 67M 7 0 
11 39F 6 1 
12 71F 17 0 
13 26F 10 1 
14 8OF 40 2 
15 29M 12 0 
16 53F 55 8 
17 69M 8 5 
18 40M 93 25 
19 63M 83 12 
Chronic congestive heart failure, prosthetic mitral valve 
Leaking abdominal aortic chronic obstructive aneurysm, 
pulmonary disease 
Cardiomyopathy, congestive heart failure, chronic obstructive 
pulmonary disease 
Warm water drowning 
Systemic lupus erythematosus 
Infected prosthetic valve, congestive heart failure 
Drug overdose 
Intracranial bleed, gastrointestinal bleed, pericarditis 
Gastrointestinal bleed 
Diabetes mellitus, hyperosmolar coma, congestive heart failure, 
chronic renal failure 
Systemic lupus erythematosus 
Gastrointestinal bleed, hepatic encephalopathy 
Recurrent pulmonary emboli 
Paraplegia, sepsis 
Budd-Chiari syndrome, hepatic failure 
Metastatic small cell carcinoma of the lung, pulmonary emboli, 
Candida pneumonia 
Cirrhosis, alcoholic hepatitis, gastrointestinal bleed 
Alcoholic liver disease, gastrointestinal bleed, esthesioblastoma 
Diabetes mellitus, artery disease, refractory congestive coronary 
heart failure 
were recorded. Thus, blood pressures during unstable 
times may be over-represented in the calculation of the 
mean systolic blood pressure for a given observation peri- 
od. 
Evidence for ATP Breakdown. Individual hypotensive 
episodes were classified on the basis of whether there was 
evidence for increased ATP breakdown or not. An episode 
interpreted as reflecting increased ATP breakdown was 
one that had either: (1) increased serum urate level, in- 
creased urine uric acid/creatinine clearance, and in- 
creased urine oxypurine/creatinine clearance, or (2) in- 
creased or unchanged serum urate level plus either in- 
creased urine uric acid/creatinine clearance or urine 
oxypurine/creatinine clearance. The comparison group for 
this determination were the mean values from the nonhypo- 
tensive observation periods immediately adjacent to the 
hypotensive episode as described previously. 
Data Analysis. The student t test was used to determine 
statistically significant changes in body fluid purine levels 
during hypotensive periods and episodes as compared with 
the appropriate nonhypotensive periods. 
Subsequently, data from all observation periods in the 19 
study patients were pooled. Body fluid ATP breakdown 
product levels during all hypotensive periods (low recorded 
systolic blood pressure 90 mm Hg or less) were compared 
with all nonhypotensive periods (low recorded systolic 
blood pressure more than 90 mm Hg). All observation 
periods were treated as being independent. The Wilcoxon 
two-group rank sum test was used to compare the means of 
the serum uric acid level, urine uric acid/creatinine clear- 
ance, and urine oxypurinelcreatinine clearance between 
the hypotensive and nonhypotensive periods. 
To evaluate whether or not changes in body fluid uric acid 
and oxypurine levels correlated with the extent of anteced- 
ent hypotension, simple linear regression analysis was 
used to quantitate relationships between body fluid purine 
levels and the lowest systolic blood pressure recorded 
during each observation period. Since a wide range of 
normal systolic blood pressures would not be expected to 
result in breakdown of ATP, the regression analysis was 
limited to observation periods with a low systolic pressure 
of 100 mm Hg or less. All statistical analyses were carried 
out using CLINFO with a Vax 1 l/730 minicomputer. 
RESULTS 
The 19 study patients included 12 females and seven 
males ranging in age from 16 to 82 years (see Table I). 
The mean serum urate, urine uric acid/creatinine clear- 
ance, and urine oxypurine/creatinine clearance levels for 
each patient during nonhypotensive (low recorded systolic 
blood pressure more than 90 mm Hg) observation periods 
are listed in Table II. A great deal of variability was present 
with mean serum urate levels ranging from 1.6 to 15.7 
mg/dl, mean urine uric acid/creatinine clearance levels 
ranging from 1.5 to 34.7 mg/ml glomerular filtrate, and 
mean urine oxypurine/creatinine clearance levels ranging 
from 0.56 to 18.12 pmol/ml glomerular filtrate. A total of 
498 observation periods were included ranging from four 
to 93 periods per patient. The group of patients who died 
in the intensive care unit averaged a longer stay than the 
other two groups and included a higher portion of the 
hypotensive observation periods (see Table Ill). 
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TABLE II Mean Body Fluid Purine Levels during 
Nonhypotensive Observation Periods 
Mean Mean 
Mean Urine Uric Acid/ Urine Oxypurine/ 
Serum Creatinine Clearance Creatinine Clearance 
Urate (mg uric acid/ (pm01 oxypurines/ 
Patient OWN ml glomerular filtrate) ml glomerular filtrate) 
1 5.4 4.3 1.47 
2 ND 1.7 1.19 
3 5.0 4.7 2.19 
4 a.9 5.8 ND 
5 1.6 3.7 2.03 
6 3.8 2.8 1.17 
7 4.0 2.3 1.37 
a 4.7 3.3 0.99 
9 4.2 5.7 0.88 
10 15.7 34.7 la.12 
11 10.6 6.6 1.57 
12 3.7 3.1 1.56 
13 2.9 1.5 0.56 
14 4.8 a.7 3.14 
15 ii.8 2.2 3.21 
16 6.5 4.9 2.26 
17 14.0 15.1 3.89 
16 2.0 2.7 1.05 
19 a.4 2.6 2.67 
ND = not determined. 
Hypotensive Observation Periods in individual Patients. 
Eleven patients had at least one hypotensive observation 
period with a low recorded systolic blood pressure of 90 
mm fig or less. A statistically significant increase in the 
urine oxypurine/creatinine clearance (p <0.05) was 
present during the hypotensive as compared with the 
nonhypotensive observation periods (see Table IV). No 
significant differences were present in the serum urate 
level or urine uric acid/creatinine clearance. 
Hypotertsive Episodes. Twenty-two separate hypoten- 
sive episodes defined by all contiguous periods with a low 
systolic blood pressure of 90 mm Hg or less were record- 
ed. This ranged from one to four such episodes per patient 
(see Table V). A statistically significant elevation in urine 
oxypurinejcreatinine clearance (p <0.05) was present 
when compared with the nonhypotensive periods. There 
was no significant difference in the serum urate level or 
urine uric acidicreatinine clearance. Figure 2 shows the 
elevation in urine oxypurine/creatinine clearance that oc- 
curred during an episode of hypotension in Patient 18. 
Hypotension was rapidly reflected in elevated excretion of 
these ATP breakdown products, suggesting that tissue 
ischemia accompanied the hypotension. 
Fifty percent (11 of 22) of the hypotensive episodes 
from all patients met our criteria for increased ATP break- 
down. There was suggestive evidence in four other epi- 
sodes (Patients 3, 8, and 16, Table V), but missing data 
preclude such a classification. Evidence for ATP break- 
down, presumably due to tissue ischemia, was usually 
present in hypotensive episodes associated with pulmo- 
nary problems. Unexpectedly, arrhythmias and gastroin- 
TABLE Ill Observation Perlods and Hypotensive 
Periods Based oh Patient Group 
Mean Number of Total Number of 
Observation Periods Hypotensive Observation 
Group per Patient (range) Periods in Group* 
Patients who lived 17.4 (4-47) 12 
(Patients 1 to 10) 
Patients discharged from 17.0 (6-40) 4 
intensive care unit 
who died during 
hospitalization 
(Patients 11 to 15) 
Patients who died in 59.8 (a-93) 50 
intensive care unit 
(Patients 16 to 19) 
* Hypotensive observation periods were defined as those in which 
a low recorded systolic blood pressure of 90 mm Hg or less was 
determined. 
TABLE IV Changes in Body Fluid Purine Levels 
during All Hypotensive Periods in a 
Patient 
Number of Total Urine Urine 
Hypolensive Number of Uric Acid/ Oxypurine/ 
Observation Observation Serum Creatinine Crealinine 
Patient Periods Periods Urale” Clearance” Clearance* 
1 2 23 114.2 43.4 94.4 
3 5 47 141 147.2 109.2 
4 3 4 100 118.1 457.2 
a 2 42 82.2 131.5 
11 1 6 94.0 166.8 80.2 
13 1 10 103.5 123.4 361.2 
14 2 40 88.8 45.7 22.2 
16 a 55 163.0 231.8 299.8 
17 5 a 79.1 83.4 238.9 
la 25 93 237.8 444.5 423.9 
19 12 a3 110.4 87.3 83.0 
NS NS p <0.05 
l The change in body fluid purine levels was expressed as percent 
of control (Table II). This was calculated by dividing the means 
from all hypotensive observation periods (low systolic blood pres- 
sure 90 mm Hg or less) by the means from all nonhypotensive 
observation periods (low systolic blood pressure more than 90 
mm Hg) in the same patient. 
testinal bleeding leading to hypotension frequently did not 
show evidence for ATP breakdown. 
Severe Hypotensive Episodes. Seven patients had se- 
vere hypotensive episodes as defined by contiguous ob- 
servation periods with a low systolic blood pressure of 90 
mm Hg or less and a mean systolic pressure of 105 mm 
Hg or less. There were 11 distinct severe episodes en- 
compassing one to 11 hypotensive observation periods in 
these patients (see Table VI). Significant differences were 
found between the means of the serum urate level (p 
<0.05) and urine oxypurine/creatinine clearance (p 
<0.05). No significant differences were present between 
the urine uric acid/creatinine clearance means. Eighty- 
two percent (nine of 11) of the severe hypotensive epi- 
sodes met our criteria suggesting increased ATP break- 
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TABLE V Changes in Body Fluid Purine Levels during Discrete Hypotensive Episodes in Individual Patients 
Urine Urine 
Uric Acid/ Oxypurinel Evidence of 
Creatinine Creatinine fncreased 















117.6 48.8 125.1 
168.2 200.3 117.1 
101.9 127.8 139.6 
ND 89.1 202.4 
100 118.1 ND 
ND 69.9 124.7 
ND 88.7 136.9 
100 157.2 71.1 
103.5 123.4 361.1 
82.6 19.5 23.9 
100 66.0 ND 
142.4 231.8 299.8 
213.7 ND ND 
67.5 55.8 57.8 
















87.0 48.4 143.7 
104.9 87.2 319.1 
523.5 1,033.8 755.8 
109.1 93.5 116.0 
68.3 86.5 69.9 
114.5 67.7 34.5 
129.2 58.8 40.0 




Atrial fibrillation with rapid ventricular response 
Respiratory arrest, unresponsive after resuscitation 





Fever, respiratory distress, pulmonary infiltrate 
Massive pulmonary embolus 
Sepsis, hypotension 
Gastrointestinal bleed 
Fever, seizures, disseminated intravascular coagulation 
Unresponsive, seizures, acute renal failure 
Pneumothorax during ventllatory support 
Hypoxia secondary to aspiration requiring intubation and 
respiratory support 
Gastrointestinal bleed, coagulopathy 
Adult respiratory distress syndrome 
Sepsis, Seizures 




* The change in body fluid purine levels was expressed as the percent pf control. This was ca!culated by dividing the means during 
hypotensive episodes (contiguous observation periods with a low recorded systolic blood pressure of 90 mm Hg or less) by the means from 
adjacent nonhypotensive observation periods (periods with a systolic blood pressure of more than 90 mm Hg). 
Nd = not determined. 
down. An additional episode (Patient 16, Table Vi) sug- 
gested such an increase, but did not meet our criteria due 
to missing data. 
Pooled Data. Analysis of the pooled data from all pa- 
tients included 66 hypotensive observation periods (low- 
est recorded systolic blood pressure 90 mm Hg or less) 
and 432 nonhypotensive periods (lowest record@ systol- 
ic blood pressure more than 90 mm Hg). Significant 
increases in the means of the serum urate level (p <0.05) 
and urine oxypurinekreatinine clearance (p <O.OOl) 
were found. There was no statistically significant differ- 
ence between the two groups for the means of the urine 
uric acidkreatinine clearance. There was no clear cutoff 
value for any body fluid purine level that would distinguish 
between hypotensive and nonhypotensive observation 
periods. 
COMMENTS 
Eleven of the 19 study patients prospectively identified as 
being severely ill with a high probability of complications 
had hypotension by our definitio?. Since serial collections 
of urine and serum samples for ATP degradation products 
were made, the hypotensive observation periods could be 
compared with the nonhypotensive periods in the *me 
patient or in aggregate. ‘A persistent finding was a signifi- 
cant irlcrease in the mean urine oxypurinekreatikne 
clearance level. These observations are in accordance 
with the elevated levels of urine and plasma oxypurines 
found in infants with perinatal distress [ 13,15-18,20,21]. 
Since significant elevations were present in the urine 
oxypurinekreatinine clearance during periods of hypo- 
tension, further analyses addressed the third question of 
whether or not a correlation existed between the degree 
of hypotension and the level of this metabolite. Simple 
linear regression analysis of the low systolic blood pres- 
sure for all observation periods with a low systolic pres- 
sure of 100 mm Hg or less with the urine oxypurinekrea- 
tinine clearance showed a correlation coefficient of r = 
-0.31 (p <O.OOl). 
Elevations of body fluid ATP degradation products re- 
sult from cellular hypoxia. The persistent finding of eleva- 
tion in the levels of oxypurjnes (hypoxan$hine and &an- 
thine) rather thaq in the serum urate or urine uric acid 
levels may be due to decreased accessibility of xanthine 
oxidase. Since uric acid is formed from hypoxanthine and 
xar$hi?e by xanthine oxidase, which is most prevalent in 
the liver and the gastrointestinal mucosa (see Figure I), 
this may reflect shunting of the blood away from the 
gastrointestinal tract during hypotension. 
There is considerable variability in appearance of in- 
creased levels of body fluid purines depending upon the 
precipitating clinical event. Pulmonary problems compli- 
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Figure 2. Effect of a hypotensive episode on urine oxy- 
purinekreatinine clearance in Patient 18. The development 
of hypotension as measured by the systolic blood pressure 
is reflected by an increase in purine excretion. Each obser- 
vation period is eight hours long. 
cated by hypotension generally showed evidence for ATP 
breakdown. Tissue hypoxia would be very likely in such a 
clinical setting. Unexpectedly, cardiac arrhythmias and 
gastrointestinal bleeding-induced hypotensive episodes 
frequently did not change levels of body fluid purines. 
Indeed, Patients 18 and 19, who had multiple hypotensive 
episodes (see Table V), showed no evidence for ATP 
breakdown when gastrointestinal bleeding and cardiac 
arrhythmias, respectively, were the underlying clinical 
events; however, hypotensive episodes from other 
causes increased their body fluid purine levels. This sug- 
gests that the physiologic consequences of hypotension 
are dependent upon the initiating event and additional 
modifying factors not defined in our study. 
The inverse correlation coefficient between the systol- 
ic blood pressure and the urine oxypurine excretion im- 
plies that more severe hypotension may result in greater 
ATP breakdown. The low correlation coefficient indicates 
that blood pressure accounts for only part of the variance. 
There are several possible explanations for this finding. 
First, individual differences in uric acid metabolism may 
occur and were not accounted for in this calculation. 
Second, blood pressure is only an indirect indicator of 
cellular hypoxia. Third, as previously discussed, the un- 
derlying clinical events may be important determinants of 
the physiologic consequences of hypotension. Finally, it 
has been suggested that body fluid purine levels them- 
selves may be the most accurate indicators of cellular 
TABLE VI Changes in Body Fluid Purine Levels 
during Severe Episodes of Hypotension 
Urine Urine 
Uric Acid/ Oxypurinel Evidence of 
Serum Crealinine Creatinine Increased 
Patient Urate” Clearance* Clearance* ATP Breakdown 
1 115.2 51.4 129.0 + 
3 232.0 309.8 358.6 + 
11 94.0 166.8 80.2 + 
13 103.5 166.9 593.1 + 
16 193.6 ND ND 
18 114.7 66.3 139.0 + 
18 101.4 70.2 182.4 + 
18 441.4 997.9 803.8 + 
19 109.8 71.8 114.3 + 
19 78.2 55.1 37.3 
19 148.4 58.1 111.1 + 
p <0.05 NS p <0.05 
* The change in body fluid purine levels was expressed as the 
percent of control. This was calculated by dividing the means from 
the severe episodes of hypotension (contiguous periods with a low 
systolic blood pressure of 90 mm Hg or less and a mean systolic 
blood pressure of 105 mm Hg or less) by the means from adjacent 
normal periods (low systolic blood pressure of more than 100 mm 
Hg and a mean systolic pressure of more than 105 mm Hg). 
ND = not determined. 
hypoxia. However, it is difficult to find a valid clinical 
measure of hypoxia to correlate with body fluid purine 
levels. 
This study of prospectively followed patients shows 
that hypotension leads to elevated urine oxypurine levels. 
Such a rise in body fluid purine levels may be of great 
physiologic and clinical importance. Adenosine, which 
traverses the cell membrane, is a potent regional vasodi- 
lator [25]. This provides a mechanism to counteract the 
ischemia and attendant cellular hypoxia that precipitated 
the ATP breakdown. On the other hand, superoxide radi- 
cals generated by xanthine oxidase during the oxidation of 
ATP degradation products to uric acid may accentuate 
tissue damage [26]. Variability in the appearance of body 
fluid ATP breakdown products during episodes of hypo- 
tension indicates the interplay of complex variables. 
There is a need to identify and study other factors that 
interact to produce cellular hypoxia. The degree of body 
fluid purine elevation may reflect the extent of cellular 
hypoxia. However, at this time, it is unclear whether single 
determinations of a purine metabolite will give useful 
estimates of the severity of a clinical event beyond indi- 
cating that the purine degradation product is normal or 
abnormal. Therefore, the use of ATP degradation prod- 
ucts to quantitate the physiologic significance of clinical 
events remains tantalizing but not proved. 
ACKNOWLEDGMENT 
We wish to thank Sally Jones for performing the measure- 
ments of body fluids, Steve Schmalz (Clinfo Systems 
Manager) for assisting in statistical methods and computer 
use, and Annette Schmidt for typing the manuscript. 
September 1986 The American Journal of Medicine Volume 61 477 













Fox IH: Metabolic basis for disorders of purine nucleotide 
degradation. Metabolism 1981; 30: 616-634. 
Chaudry Il-l, Sayeed MM, Baue AE: Alterations in high-energy 
phosphates in hemorrhagic shock as related to tissue and 
organ function. Surgery 1976; 79: 666-668. 
Chaudry IH, Sayeed MM, Baue AE: Differences in the altered 
energy metabolism of hemorrhagic shock and hypox- 
emia. Can J Physiol Pharmacol 1976; 54: 750-756. 
Chaudry IH, Sayeed MM, Baue AE: Effect of hemorrhagic 
shock on tissue adenine nucleotides in oonscious rats. 
Can J Physiol Pharmacol 1974; 52: 131-137. 
Ukikusa M, Kamiyama Y, Sato T, et al: Pathophysiology of 
hemorrhagic shock. II. Anoxic metabolism of the rat liver 
following acute blood loss in the rat. Circ Shock 1981; 8: 
483-490. 
Chaudry IH, Wichterman KA, Baue AE: Effect of sepsis on 
tissue adenine nucleotide levels. Surgery 1979; 85: 
205-211. 
Simeone FA, Abraham J, Hopkins RW, Damewood CA: 
Levels of allantoin and uric acid in dogs subjected to 
hemorrhagic shock. J Surg Res 1975; 19: 373-380. 
Cunningham SK, Keaveny TV: Splanchnic organ adenine 
nucleotides and their metabolites in haemorrhagio shock. 
Ir J Med Sci 1977; 146: 136-143. 
Aasen AO, Saugstad OD: Hypoxanthine in lethal canine 
endotoxin shock. Circ Shock 1979; 6: 277-283. 
Karlsson J, Willerson JT, Leshin SJ, Mullins CB, Mitchell JH: 
Skeletal muscle metabolites in patients with cardiogenic 
shock or severe congestive heart failure. Stand J Clin 
Lab Invest 1975; 35: 73-79. 
Woolliscroft JO, Colfer H, Fox IH: Hyperuricemia in acute 
illness: a poor prognostic sign. Am J Med 1982; 72: 
58-62. 
Buhl L, Vilhelmsen KN, Nielsen JR: Oxypurine release in 
cardiac disease. Acta Med Stand 1981; 209: 83-86. 
Saugstad OD: Hypoxanthine as a measurement of hypoxia. 
Pediatr Res 1975; 9: 158-161. 














Swanstrom S, Bratteby L: Hypoxanthine as a test of perinatal 
hypoxia as compared to lactate, base deficit, and pH. 
Pediatr Res 1982; 16: 156-160. 
Thiringer K: Cord plasma hypoxanthine as a measure of 
faetal asphyxia. Acta Paediatr Scand 1983; 72: 231-237. 
Manzke H, Dorner K, Grunitz J: Urinary hypoxanthine, xan- 
thine and uric acid excretion in newborn infants with 
perinatal complications. Acta Paediatr Stand 1977; 66: 
713-717. 
Jensen MH, Brinklov MM, Lillquist K: Urinary loss of oxypur- 
ines in hypoxic premature neonates. Biol Neonate 1980; 
38: 40-48. 
Mehes K, Horvath I, Szakolczai I: Uric acid in a single urine 
sample from neonates with perinata! hypoxia. Acta Pae- 
diatr Acad Sci Hung 1981; 22: 43-47. 
Harkness RA, Whitelow AGL, Simmonds RJ: lntrapartum 
hypoxia: the association between neurological assess- 
ment of damage and abnormal excretion of ATP metabo- 
lites. J Clin Pathol 1982; 35: 999-1007. 
Harkness RA, Simmonds RJ, Coade SB, Lawrence CR: Ratio 
of the concentration of hypoxanthine to creatinine in urine 
from newborn infants: a possible indicator for the meta- 
bolic damage due to hypoxia. Br J Obstet Gynaecol 1983; 
90: 447-452. 
Liddle L, Seegmiller JE, Laster L: The enzymatic spectro- 
photometric method for determination of uric acid. J Lab 
Clin Med 1959; 54: 903-913. 
Klinenberg JR, Goldfinger S, Bradley KH, Seegmiller JE: An 
enzymatic spectrophotoqetric method for the determina- 
tion of xanthine and hypoxanthine. Clin Chem 1967; 13: 
834-846. 
Technicon Auto Analyzer R method file 1969. Method N 116. 
Technicon Instruments Corporation, Tarrytown, New 
York. 
Berne RM: Cardiac nucleotides in hypoxia: possible role in 
regulation of coronary blood flow. Am J Physiol 1963; 
204: 317-322. 
McCord JM: Oxygen-derived free radicals in postischemic 
tissue injury. N Engl J Med 1985; 312: 159-163. 
478 September 1988 The American Journal of Medicine Volume 81 
